

# Pz-1

**Catalog No: tcsc0035381**



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg



## Specifications

**CAS No:**

1800505-64-9

**Formula:**

$C_{26}H_{26}N_6O_2$

**Pathway:**

Protein Tyrosine Kinase/RTK

**Target:**

VEGFR

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**

454.52

## Product Description


Pz-1 is a potent **RET** and **VEGFR2** inhibitor with **IC<sub>50</sub>**s of less than 1 nM for both wild type kinases.

IC50 & Target: IC50: [1]

***In Vitro:***

Pz-1 is a Type-II tyrosine kinase inhibitor, able to bind the DFG-out conformation of the kinase. In cell-based assays, 1.0 nM of Pz-1 strongly inhibits tyrosine phosphorylation of VEGFR2 and clinically relevant RET mutants, including those refractory to vandetanib and cabozantinib (RET<sup>V804M</sup> and RET<sup>V804L</sup>)<sup>[1]</sup>.

***In Vivo:*** Pz-1 is shown active on VEGFR2, which can block blood supply required for RET-stimulated growth. At 1.0 mg/kg/day per os, Pz-1 abrogates formation of tumors induced by RET-mutant fibroblasts and blocks phosphorylation of both RET and VEGFR2 in tumor tissue. Pz-1 features no detectable toxicity up to 100.0 mg/kg, which indicates a large therapeutic window<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!